scispace - formally typeset
Journal ArticleDOI

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Reads0
Chats0
TLDR
Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.
Abstract
PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-y...

read more

Citations
More filters
Journal ArticleDOI

4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway.

TL;DR: It is demonstrated for the first time that 4-MD exerts in vitro and in vivo anti-proliferative effects against osteosarcoma cells through the inhibition of the JAK2/STAT3 pathway, and suggested the potential for therapeutic application of 4- MD in the treatment of osteosARcoma.
Journal ArticleDOI

Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1.

TL;DR: It is indicated that macrophage-derived CCL18 promotes OS proliferation and metastasis via the EP300/UCA1/Wnt/β-catenin pathway and that CCL 18 may be used as a prognostic marker and therapeutic target of OS.
Journal ArticleDOI

Treatment of primary malignant bone tumours of the distal tibia

TL;DR: In larger defects in children, allograft with vascularised fibula is an acceptable alternative, but amputation still has a role in this group, and in adults, endoprosthetic replacement with proper soft tissue coverage is a viable option in cases with large bony defects.
Book ChapterDOI

Expandable endoprostheses in malignant bone tumors in children: indications and limitations.

TL;DR: Innovative expandable endoprosthetic devices are now available to help achieve equal limb length at maturity, with one advantage of the "bioexpandable" system is that with sequential lengthening, the proportion of residual bone shaft to prosthesis length increases, thereby diminishing host bone-endoprosthesis lever arm forces.
Journal ArticleDOI

Telangiectatic osteosarcoma: a review of 87 cases

TL;DR: TOS does not have a poor prognosis as previously reported in literature, with a survival of about 60 % at 10 years, even if small tumor volume at diagnosis correlates with better prognosis at univariate analysis.
References
More filters
Book ChapterDOI

Nonparametric Estimation from Incomplete Observations

TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI

Regression Models and Life-Tables

TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI

Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

TL;DR: There is substantial under representation of patients 65 years of age or older in studies of treatment for cancer, and the reasons should be clarified, and policies adopted to correct this underrepresentation.
Related Papers (5)